UBR2 (Gene)

Synonyms:C6orf133, ENTREZ:23304, HGNC:21289, MIM:609134, NM_001184801, NM_001363705, NM_015255, NP_001171730, NP_001350634, NP_056070, UBR2, XM_005248966, XM_011514438, XM_011514439, XM_011514440, XM_011514441, XM_017010594, XM_017010595, XM_017010596, XM_017010597, XP_005249023, XP_011512740, XP_011512741, XP_011512742, XP_011512743, XP_016866083, XP_016866084, XP_016866085, XP_016866086, XR_001743284, XR_001743285, bA49A4.1, dJ242G1.1, dJ392M17.3, ubiquitin protein ligase E3 component n-recognin 2
Omim:OMIM:609134
Id:ENSG00000024048
Hgnc:HGNC:21289
Entrez:23304
Description:ubiquitin protein ligase E3 component n-recognin 2
Enables leucine binding activity. Involved in cellular response to leucine and negative regulation of TOR signaling. Predicted to be located in cytosol. Predicted to be part of ubiquitin ligase complex. Predicted to be active in cytoplasm. Predicted to colocalize with chromatin. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View UBR2's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with UBR2.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using UBR2.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for UBR2.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with UBR2.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.